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Vascular smooth muscle cell (VSMC) proliferation remains a major cause of veno-arterial graft failure. We
hypothesised that exposure of venous SMCs to arterial pressure would increase KLF5 expression and that
of cell cycle genes. Porcine jugular veins were perfused at arterial or venous pressure in the absence of
growth factors. The KLF5, c-myc, cyclin-D and cyclin-E expression were elevated within 24 h of perfusion
at arterial pressure but not at venous pressure. Arterial pressure also reduced the decline in SM-myosin
heavy chain expression. These data suggest a role for KLF5 in initiating venous SMCs proliferation in
response to arterial pressure.
 2009 Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
The saphenous vein is a commonly used conduit in bypass
grafting. Whilst saphenous vein grafts have patency rates of
approximately 85% at 1 year by 10 years this has fallen to between
30% and 50% [1]. Intimal hyperplasia is the main cause of vein graft
failure after the ﬁrst month [2] making it important to understand
the mechanisms that regulate vascular smooth muscle cell (VSMC)
proliferation. One factor that may contribute to intimal hyperplasia
in veno-arterial grafts is the exposure of venous SMCs to arterial
pressure. The involvement of this factor is supported by the differ-
ent gene expression proﬁles of venous and arterial SMCs. Further-
more, exposure of cultured venous SMCs to stretch has been shown
to regulate cell proliferation [3]. However, there are likely to be
marked differences between the responses of cells that have been
dispersed in culture to those that remain in the intact vessel.
Therefore, the effects of pressure on VSMC phenotype and prolifer-
ation in the vessel remain to be determined.
The phenotype of proliferating VSMCs differs from that of quies-
cent cells in the vessel media [4]. To proliferate, the cells must ex-
press cell cycle genes as well as the transcription factors that
activate their expression. One transcription factor that is importantrafting; LIMA, left internal
ll; SM-MHC, smooth muscle
omain 1; KLF5, Krüppel-like
).
Y-NC-ND license.in VSMCproliferation is theKrüppel-like transcription factor 5, KLF5
[5], which activates a number of cell cycle genes including cyclin-D
[6]. KLF5 expression has been shown to be elevated in response to
stent induced vascular injury [5] and in rabbit models of grafting
[7]. VSMCs in lesions also showalteredexpressionof contractile pro-
teinswith reduced expression of the smoothmuscle contractile pro-
teins and their replacement with non-muscle equivalents [8] a
process that has been associated with KLF5 expression [9].
Previous studies have used perfusion systems to simulate the
exposure of veins to arterial pressure. These studies have identiﬁed
changes in the expression of tissue factor [10] and the matrix
metalloproteinases [11] and modiﬁcation of vascular remodelling
[12]. However, the effect of arterial pressure on VSMC phenotype
and the cell cycle remains uninvestigated. In part this may is be-
cause of the presence of foetal calf serum in the perfusate exposing
the cells to growth factors that would modify gene expression and
initiate proliferation independent of mechanical stimulation. In this
study, we tested the novel hypothesis that exposure of veins to
arterial pressure induces KLF5 expression and enhances SMC prolif-
eration. Thus, we examined the effect of exposing veins to arterial
and venous pressure in a perfusion system for 48 h on gene expres-
sion. The veins were cultured in the absence of exogenous growth
factors to identify changes dependent on perfusion pressure.
Materials and methods
Perfusion apparatus. Block dissections of the carotid sheath of
adult pigs were obtained from Cheale Meats, Essex, UK, and stored
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penicillin and streptomycin for transport to the laboratory. The
internal jugular veins were dissected with aseptic technique and
kept in cold DMEM as above. The veins were tied to universal 3-
way taps with surgical ligatures and connected to each other in
parallel with 4 vein segments in each experiment. Each vein piece
used was taken from a separate animal.
The veins were transferred to a specially produced aluminium
chamber with built-in adaptors for the 3-way taps to be connected
to quarter inch cardio-pulmonary bypass circuit tubing and con-
nectors for removable gas exchange membranes. The tubing was
connected to a cardio-pulmonary bypass pump with De Bakey roll-
er pumps (Sorin Group, Milan, Italy) and an aneroid manometer
(Tycos) between the pump and the inlet of the perfusion chamber.
DMEM with the above antibiotics was used for both perfusing the
veins and to maintain the veins in the chamber. Oxygen and carbon
dioxide were supplied separately through their own dedicated gas
exchange membranes in the chamber. The design of the connec-
tions was such that the perfusate from the veins drained into the
chamber allowing mixing of the maintenance medium in order
to ensure maximum oxygen delivery. The entire chamber was kept
in a water bath at 37 C. The veins were then perfused under arte-
rial (80–85 mmHg) or venous (5 mmHg) pressure.
For each replicate experiment samples exposed to venous or
arterial pressure were obtained by removing the vein from the
apparatus at 0 (control), 12, 24, 36 or 48 h. Five millimeters of vein
adjacent to each 3-way tap was discarded to avoid tissue respond-
ing to damage due to the ligature. All ﬁbrous tissue was removed
from the remainder of the sample which was placed into RNA later
and frozen. All samples were stored at 80 C.
RNA preparation and quantitative real-time PCR. RNA was ex-
tracted from tissue by pulverising the tissue under liquid nitrogen.
The RNA was quantiﬁed using a nanodrop spectrophotometer and
125 ng of RNA was reverse transcribed using superscript II follow-
ing the manufacturer’s recommendations (Invitrogen). Quantita-
tive PCR was performed as previously described [13] using
primers designed to recognise particular porcine genes which were
identiﬁed by BLAST searching of the non-redundant (NR) and ex-
pressed sequenced tag (EST) databases. Where possible, primers
were designed to amplify across exon–exon boundaries. Primer se-
quences are provided in Table 1. PCR products were cloned and se-Table 1
Primer sequences used in this study.
SM22a for GGTCTGGCTGAAGAATGGCGTGATTTT
SM22a rev CTGAGCCACCTGCTCCATTTGCTTG
SMa–Actin for GGAGCGTGGCTACTCCTTCGTGA
SMa–Actin rev CGTCAGGCAGCTCGTAGCTCTTCT
18S for GTAACCCGTTGAACCCCATT
18S rev CCATCCAATCGGTAGTAGCG
FHL1C R GGGAGGACTTCTACTGCGTGACTTG
FHL1C F ATGCCAGGGCTGATCCTGGTAAG
Pig myocardin F1 CCGCCTGCATTCCATGAGCAAAG
Pig myocardin R1 CCTCTCTGCACTGGAGGCTTGGAGTATG
KLF5 R1 CACCCTGCCAGTTAATTCCCAAAAC
KLF5 F2 CCCAGGTGCACTTGTAGGGCTTCTC
NM-MHC for CAATAAAGCTCTGGACCGGACCAAAC
NM-MHC rev GTCGAGGCCGAAGTCGATGAAGTTC
SM-MHC for CAGGCGAGTCTGGAGCTGGGAAAAC
SM-MHC rev CCACGATGTAACCCGTGACGTCAAAG
Cyclin D2 for CCCCACGACTTCATCGAGCACATT
Cyclin d2 rev GCTGTTGAGCAGCACGACCTCAATC
c-myc for GCCCACGACTCGCTCCTCTGAAAG
c-myc rev GGTGGGCAGCAACTCGAATTTCTTC
c-fos for GTCCCCAGAAGAAGAAGAGAAAAGGAGAATC
c-fos rev CCCACTCAGATCAAGGGAAGCCAC
cyclin E2 for GTGACGGTCATCTCCTGGCTAAATC
cyclin E2 rev CCCATTCCAAACCTGAGGCTTTCquenced to conﬁrm the validity of the ampliﬁcation reaction.
Quantitative PCR reactions were performed using SYBR green and
analysed as described previously [13].
Statistical analysis. Data were analysed using an unpaired stu-
dents T test to determine signiﬁcance. Correlations were per-
formed using the spearman rank correlation.Results
Arterial pressure increases KLF5 expression
Quantitative PCR for KLF5 showed a greater than 10-fold in-
crease in the expression of KLF5 within 12 h of the exposure to
arterial pressure that remained elevated throughout the experi-
ment. KLF5 expression did not increase in veins exposed to venous
pressure until after 48 h of perfusion and this increase was much
smaller (4-fold) than in the veins perfused at arterial pressure
(Fig. 1A).
Arterial pressure increases cell cycle gene expression
Analysis of the mRNA for c-myc and c-fos showed that expres-
sion of c-myc was markedly elevated 24 h after the exposure of
veins to arterial pressure. c-myc expression then declined but re-
mained elevated at 36 h (Fig. 1B). There was no change in c-myc
in veins perfused at venous pressure. At all time points during
the perfusion the expression of c-fos was markedly reduced com-
pared to c-fos expression 0 h (Fig. 1C). However, within the perfu-
sion period the kinetics of expression of c-fos was similar to c-myc,
i.e. elevated at 24 h compared to 12 h and 36 h. c-fos expression is
normally low or undetectable in VSMCs in vessels but is elevated
by mechanical treatment [14] making it likely that the preparation
of the vessels for perfusion activated c-fos expression giving an
anomalously high value for c-fos at 0 h and that the activation of
c-fos observed at 24 h reﬂects an increase in c-fos in response to
the exposure to arterial pressure.
Quantitative PCR also identiﬁed an increase in cyclin-D and cy-
clin-E expression in response to arterial pressure. Cyclin-D expres-
sion was elevated 3-fold after 24 and 36 h of exposure to arterial
pressure but this was signiﬁcant only for the 36 h time point. Cy-
clin-E expression was also elevated at 24 h (4-fold) then declined
to 2-fold over baseline by 48 h (data not shown). Veins exposed
to venous pressure showed a much smaller increase in cyclin-E
at 24 h but by 48 h the expression of cyclin-E had increased 8-fold.
Effects of pressure on smooth muscle cell phenotype
The expression of SM-MHC, SM a-actin and SM22a (markers of
VSMC phenotype) was reduced by the perfusion process irrespec-
tive of perfusion pressure. At arterial pressure the expression of
SM-MHC (Fig. 2A) and SM22a (Fig. 2C) were reduced 50% within
12 h and then remained stable. SM a-actin expression (Fig. 2B)
was reduced by 80% over the same time period. At venous pressure
SM-MHC expression fell by 90% within 48 h and SM22a expression
fell by 50% over the same time period. SMa-actin levels were also
reduced at 24 h but increased over the subsequent 24 h (Fig. 2).
The expression of myocardin an important transcription coactiva-
tor in VSMCs [15] did not change in response to perfusion at arte-
rial pressure. However, at venous pressure myocardin expression
fell by 70% within 48 h (Fig. 2D).
The four and half LIM domain protein FHL1, is also a potential
regulator of VSMC phenotype [16]. FHL1 expression fell in re-
sponse to perfusion but the reduction in expression was greater
in vessels exposed to venous compared to arterial pressure
(Fig. 3A). FHL1 expression was positively correlated with SM-
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Fig. 1. Expression of genes associated with smooth muscle phenotype. Quantitative real-time PCR analysis for (A) KLF5, (B) c-myc, (C) c-fos and (D) cyclin-D obtained as
described in Materials and methods. Data are presented as average fold change ± SEM from control normalised to 18S RNA. (Arterial pressure, n = 7 for KLF5 and 5 for the cell
cycle genes, venous pressure n = 4.) Open bars: arterial pressure, solid bars: venous pressure. (*p < 0.05, **p < 0.01 compared to t = 0.)
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Fig. 2. Expression of genes associated with smooth muscle phenotype. Quantitative real-time PCR analysis for (A) SM-MHC, (B) SMa-actin, (C) SM22a and (D) myocardin
obtained as described in Materials and methods. Data for each test RNA were normalised to the expression of 18S RNA from the same sample. Data are presented as average
fold change ± SEM from control normalised to 18S RNA. (Arterial pressure, n = 7, venous pressure n = 4). Open bars: arterial pressure, solid bars: venous pressure. (*p < 0.05,
**p < 0.01 compared to t = 0.)
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Fig. 3. Expression of FHL1 and NM-MHC in veins. Quantitative real-time PCR analysis for (A) FHL1, and (B) NM-MHC obtained as described in Methods. Data are presented as
average fold change ± SEM from control normalised to 18S RNA. (Arterial pressure, n = 7, venous pressure n = 4.) Open bars: arterial pressure, solid bars: venous pressure.
(*p < 0.05, **p < 0.01 compared to t = 0.) Correlation of NM-MHC and KLF5 expression at (C) arterial pressure, and (D) venous pressure.
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(q = 0.82, p < 0.0001, q = 0.86, p < 0.0001, q = 0.61, p < 0.01, respec-
tively, Fig. 4). The correlation was maintained in the samples per-
fused at venous pressure for FHL1 with SM22a (q = 0.78, p = 0.05)
and SMa -actin (q = 0.81, p = 0.03) but not with SM-MHC.
In veins exposed to arterial pressure the expression of NM-MHC
mimicked the expression of SM-MHC, reducing by approximately
50% within 12 h then remained stable. In contrast in veins perfused
at venous pressure NM-MHCexpression initially fell but returned to
the control level by the end of the experiment (Fig. 3B). The expres-
sion of NM-MHC was correlated with KLF5 expression (q = 0.79,
p = 0.037) at venous but not at arterial pressure (Fig. 3C and D).Discussion
Our data show that perfusion of veins at arterial pressure in-
creases the expression of KLF5 that is followed by increased
expression of c-myc, cyclin-D and cyclin-E. KLF5 expression has
previously been shown to be associated with the proliferative phe-
notype of VSMCs. For example, KLF5 is expressed in proliferating
VSMCs in vivo in both transplant arteriosclerosis [7] and in models
of restenosis [5] (e.g. in response to stenting). Indeed, KLF5 is likely
to contribute to the initiation or progression of the cell cycle in
arterial VSMCs as in KLF5+/ mice, the expression of platelet de-
rived growth factor-A (PDGF-A) is reduced and the mice have a re-
duced proliferative response to injury [17]. Similarly inhibition of
KLF5 expression and activity inhibits arterial VSMC proliferation
in vivo [5].
A role for KLF5 in VSMC proliferation and our demonstration of
increased expression of cell cycle genes are consistent with the
known effects of KLF5 in other cells. KLF5 is known to activatethe expression of cyclin-D1 and cyclin-B1 [6] and reduce the
expression of the CDK inhibitors [18]. In the case of cyclin-D1 this
increase results from binding of KLF5 to the cyclin-D1 promoter [6].
These data suggests that the exposure of venous SMCs to arte-
rial pressure elevates KLF5 expression thereby activating expres-
sion of cell cycle genes. We propose that these changes initiate
VSMC proliferation which can lead to occlusion of the transplanted
vein and graft failure.
The increase in KLF5 might have been expected to be associated
with an increase in NM-MHC [9]. However, exposure to arterial
pressure reduced the expression of NM-MHC. Furthermore, whilst
KLF5 expression was correlated with NM-MHC expression at ve-
nous pressure there was no association at arterial pressure. These
data indicate that increased pressure suppresses NM-MHC expres-
sion and the increase in KLF5 is not sufﬁcient to overcome this
inhibition.
The expression of both KLF5 and cyclin-E showed signiﬁcant in-
creases in samples perfused at venous pressure compared to con-
trols after 48 h. In the perfusion system the veins become
slightly distended even at venous pressure and it may be that this
distension is sufﬁcient to cause the increase in KLF5 and cyclin-E
after a prolonged period of time. Alternatively it is possible that
these changes are the result of perfusion for an extended period
of time in the absence of plasma proteins.
The reduction in the expression of SM-MHC, SM22a and SM a-
actin in response to perfusion is consistent with studies of cultured
arterial SMCs [8]. However, the smaller reduction and the stabilisa-
tion of SM-MHC and SM22a expression at arterial compared with
venous pressure suggest that tension in the vessel wall contributes
to the expression these genes. This observation is consistent with
previous observations that the expression of smooth muscle-spe-
ciﬁc genes is regulated by pressure in the developing pulmonary
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Fig. 4. Correlation of FHL1 expression with SM-MHC and SM22a at arterial and venous pressure. The expression of FHL1 was compared to the expression of (A) and (C)
SM22a and (B) and (D) SM-MHC in the same sample. All samples perfused at either arterial (A and B) or venous pressure (C and D) were included in the analysis irrespective
of the length of perfusion. q is quoted statistically signiﬁcant correlations (p < 0.01).
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expression of caldesmon and ﬁlamin in organ culture [20]. Given
the importance of myocardin to VSMC differentiation it is perhaps
surprising that the reduction in the expression of the smooth
muscle contractile genes was not accompanied by a reduction in
myocardin expression. This observation implies that myocardin
does not contribute to the regulation of gene expression by wall
tension.
Over expression of FHL1 has been shown to increase SM-MHC
expression in SMCs [21]. FHL1 interacts with components of the
cytoskeleton [22] and with transcription factors and shuttles be-
tween the cytoplasm and the nucleus [23] making it an ideal reg-
ulator of gene expression in response to cytoskeletal changes. Our
data showing a strong positive correlation of FHL1 and SM-MHC
expression when veins were perfused under arterial pressure but
not venous pressure suggests either that FHL1 and SM-MHC are
regulated by similar mechanisms under these conditions or that
FHL1 contributes to the control of SM-MHC expression in response
to pressure. Consistent with this suggestion we have also found a
similar correlation between FHL1 expression and SM-MHC in car-
otid arteries and transplanted jugular veins but not in normal jug-
ular veins of pigs (EA and PRK manuscript in preparation).
In conclusion our data show that cells respond to the increase in
pressure by increasing the expression of KLF5 and inducing the
expression of genes associated with the cell cycle. This increase
in KLF5 is likely to be important in the initiation of the cell cycle
and the development of intimal hyperplasia. Higher pressure also
maintains higher levels of SM-MHC expression and alters the asso-
ciation between FHL1 and SM-MHC implicating FHL1 in the
expression of SM-MHC under high pressure.Acknowledgments
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